^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATG-022

    i
    Other names: ATG-022
    Company:
    Antengene
    Drug class:
    CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    8ms
    CLINCH: A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Antengene Biologics Limited | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN18 (Claudin 18)
    |
    ATG-022
    over1year
    CLINCH: A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=156, Not yet recruiting, Antengene Biologics Limited
    New P1 trial • Metastases
    |
    CLDN18 (Claudin 18)
    |
    ATG-022
    2years
    ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts (AACR 2022)
    The monoclonal antibody targeting CLDN18.2 (IMAB362) has demonstrated promising clinical benefit in combination with chemotherapies for gastric cancer patients. ATG-022 demonstrated potent in vitro and in vivo antitumor effects, with in vivo efficacy observed in CLDN18.2-low expression PDX models, suggesting a promising therapeutic strategy for gastric cancer patients with a broad range of CLDN18.2 expression levels.
    Preclinical
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression • CLDN18.2 underexpression
    |
    Vyloy (zolbetuximab) • ATG-022